Zhang Mingxuan, Guo Ruiping, Yuan Zhuhui, Wang Hao
Department of Radiation Oncology Cancer Center of Peking University Third Hospital Peking University Third Hospital Haidian, 49 Huayuan North Road Beijing 100191 China.
Glob Chall. 2024 Nov 25;9(1):2400217. doi: 10.1002/gch2.202400217. eCollection 2025 Jan.
Hepatocellular carcinoma (HCC) stands as the predominant form of primary liver cancer, characterized by a dismal prognosis. Therapeutic options for advanced HCC remain sparse, with efficacy significantly hampered by the emergence of drug resistance. In parallel with research into novel pharmacological agents, advances in drug delivery systems represent a promising avenue for overcoming resistance. Lipid nanoparticles (LNPs) have demonstrated considerable efficacy in the delivery of nucleic acid-based therapeutics and hold potential for broader applications in drug delivery. This review describes the development of LNPs tailored for HCC treatment and consolidates recent investigations using LNPs to target HCC.
肝细胞癌（HCC）是原发性肝癌的主要形式，预后不佳。晚期HCC的治疗选择仍然有限，耐药性的出现严重阻碍了疗效。在研究新型药物的同时，药物递送系统的进展是克服耐药性的一个有前景的途径。脂质纳米颗粒（LNPs）在递送基于核酸的治疗药物方面已显示出相当大的疗效，并在药物递送中有更广泛应用的潜力。这篇综述描述了为HCC治疗量身定制的LNPs的发展，并汇总了最近使用LNPs靶向HCC的研究。
